Last reviewed · How we verify
NCT06086821
Clinical Relevance of Different Time of Periodontal Re-evaluation
NA trial testing Periodontal Re-Evaluation in Periodontal Diseases in 40 participants. Completed in 1 February 2025.
1 September 2024
Quick facts
| Lead sponsor | University of Florence |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 15 October 2023 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 February 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Periodontal Re-Evaluation
Conditions studied
- Periodontal Diseases — all drugs for Periodontal Diseases →
Sponsor
University of Florence
Who can join
18 and older, any sex, with Periodontal Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Treatment of periodontitis follows an incremental step approach. The results after step 1 (Oral Hygiene Instruction and Professional Mechanical Plaque Removal) and 2 (subgingival instrumentation) are re-evaluated in order to understand whether the endpoints of therapy have been achieved. The case reevaluation may be performed at different time intervals, ranging from 2 weeks to 6 months. The aim of this study is to compare two different timing of re-evaluation, in terms of clinical indexes (PPD reduction; Pocket closure) and patients' morbidity (number of further therapies needed).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Timing of Re-Evaluation After Periodontal Therapy: A Randomized Clinical Trial.
Castelluzzo W, Rupe C, Nieri M, di Martino M, et al · · 2026 · PMID 41664833 · DOI 10.1111/jre.70086
Verify or expand the search:
- PubMed search for NCT06086821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Periodontal Diseases
Currently open trials in the same condition.
- NCT07358104 — Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects · NA · active not recruiting
- NCT07312045 — HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical T · recruiting
- NCT07384221 — Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients · recruiting
- NCT07530978 — ORAL HYGIENE, PERIODONTAL STATUS AND QUALITY OF LIFE · recruiting
- NCT06848790 — Interdental Hygiene Methods in Young Adults · NA · recruiting
Other University of Florence trials
Trials by the same sponsor.
- NCT06628921 — The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study) · recruiting
- NCT06123000 — Modified Widman Flap vs Fibre Retention Osseous Resective Surgery · NA · recruiting
- NCT06135753 — Psychosomatic Intervention in Fibromyalgia. · NA · recruiting
- NCT06884553 — Robotic Rehabilitation Vs Occupational Therapy Chronic Stroke Upper Limb Rehabilitation · NA · recruiting
- NCT05903027 — Gepant treAtments: EffectIveNess and tolERability (GAINER) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06086821 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florence
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06086821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing